Tech Company Financing Transactions

NGM Biopharmaceuticals Funding Round

NGM Biopharmaceuticals secured a $50 million Series C funding round on 7/19/2013. Backers included Prospect Venture Partners, Rho Ventures and The Column Group.

Transaction Overview

Announced On
Transaction Type
Venture Equity
Series C

Prospect Venture Partners (David Schnell)

Rho Ventures (Mark Leschly)

The Column Group (David Goeddel)

Tichenor Ventures (McHenry Tichenor)

Topspin Partners

Proceeds Purpose
Specific proceeds purposes were not disclosed.

Company Information

Company Status
Mailing Address
333 Oyster Point Blvd.
San Francisco, CA 94080
Email Address
NGM Biopharmaceuticals (Nasdaq: NGM) is a privately-held drug discovery company committed to the identification and development of transformational biologics for diabetes, obesity, muscle wasting and other cardiometabolic diseases.
NGM Biopharmaceuticals LinkedIn Company Profile
Social Media
NGM Biopharmaceuticals Company Twitter Account
Company News
NGM Biopharmaceuticals News
NGM Biopharmaceuticals on Facebook
NGM Biopharmaceuticals on YouTube

Management Team

Email & Social
William Rieflin
  William Rieflin LinkedIn Profile  William Rieflin Twitter Account  William Rieflin News  William Rieflin on Facebook
Chief Executive Officer
David Woodhouse
  David Woodhouse LinkedIn Profile  David Woodhouse Twitter Account  David Woodhouse News  David Woodhouse on Facebook
Chief Medical Officer
Alex DePaoli
  Alex DePaoli LinkedIn Profile  Alex DePaoli Twitter Account  Alex DePaoli News  Alex DePaoli on Facebook
Chief Scientific Officer
Jin-Long Chen
  Jin-Long Chen LinkedIn Profile  Jin-Long Chen Twitter Account  Jin-Long Chen News  Jin-Long Chen on Facebook
Vice President
Wenyan Shen
  Wenyan Shen LinkedIn Profile  Wenyan Shen Twitter Account  Wenyan Shen News  Wenyan Shen on Facebook
VP - R & D
Hui Tian
  Hui  Tian LinkedIn Profile  Hui  Tian Twitter Account  Hui  Tian News  Hui  Tian on Facebook



Browse more venture capital transactions:

Prev: 7/19/2013: Nifti venture capital transaction
Next: 7/19/2013: Zurex Pharma venture capital transaction


Share this article


Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary